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It  is  clear  that  the  activation of T  lymphocytes for helper  (1-3),  cytotoxic  (4), 
delayed type hypersensitivity (5), and antigen-induced proliferative (6,  7) responses 
requires  their  interaction  with  a  specialized  antigen-presenting  cell  (APC) 1 that 
expresses I-region-associated (Ia) antigens. Cells of the monocyte-macrophage lineage 
(8, 9), including the liver Kupffer eell (10) and the Langerhan's cell of the epidermis 
(11) as well as the recently described dendritic cell (12),  have all been shown to be 
effective APC  and  in  addition  to  serve  as  stimulator cells  in  mixed  lymphocyte 
reactions (13). Antigen-specific T  cells appear to recognize a complex of antigen and 
Ia molecules on the surface of such an APC, and such "joint recognition" is responsible 
for the phenomenon of major histocompatibility complex (MHC) restriction. How- 
ever, the biochemical nature of the antigen processing event and the sequence of the 
T  celI-APC signals that result in a T  cell response have remained difficult to dissect 
largely because of technical problems in obtaining sufficiently large numbers of highly 
purified APC. 
A tumor cell line that possesses APC ability would clearly be an extremely useful 
tool; however, the macrophage-like tumor lines characterized thus far appear to have 
little or no surface Ia antigen and are largely deficient in APC ability (14). Recently, 
Chesnut  and  Grey  (15) have  presented  data  that  normal  B  cells  under  certain 
circumstances can present antigen to T cells. Indeed, Schwartz et al. (16) and Chesnut 
and  Grey  (personal  communication)  have  presented  preliminary data  that  an  Ia 
antigen-bearing B cell tumor line could serve as an APC for antigen-reactive T  cells. 
Certainly it appears  that  the B  cell must  be capable  of presenting the antigen-Ia 
complex to T  lymphocytes because cloned lines of T  lymphocytes can interact in an 
antigen-specific,  MHC-restricted  fashion  with  B  cells  after  initial  activation  by 
marophages (17). 
In this paper, we report that several but not all of a series of Ia antigen-positive B 
cell tumor lines are capable of presenting both alloantigens and protein antigens to 
I  ......  Abbrevtatzons used m  thzs paper:  APC, antigen presenting cell; C, complement; CFA, complete Freund s 
57  35  adjuvant; GI~, poly(Glu  Lys  PheS); Ia, I region associated; IL-1, interlcukin 1; IL-2, interleukin 2; LN, 
lymph node; MHC, major histocompatibility complex;  MLR, mixed lymphocyte response; OVA, oval- 
bumin; PMA, phorbol myristic  acetate;  PPD,  purified protein derivative  of tuberculin; SAC, splenic 
adherent cells. 
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alloreactive and antigen-reactive T  lymphocytes in an MHC-restricted  fashion. The 
addition of interleukin  1 (IL- 1) is necessary for the stimulation of allogeneic responses 
and, although not necessary, did potentiate antigen-specific responses. The activation 
of alloreactive T  cells is blocked by the inclusion in the cultures of specific monoclonal 
anti-Ia antibodies.  Furthermore,  it  is possible  to obtain an antigen-specific response 
by pulsing the tumor cells with antigen, although the continuous presence of soluble 
antigen  in  the  culture  system  results  in  a  superior  response.  These  tumor cells,  by 
comparison with conventional APC, should prove useful in studying the biochemical 
events that occur during antigen processing and the requirements for T  cell triggering 
by processed antigen in association with Ia molecules. 
Materials  and Methods 
Animals.  B 10.A, C57BL/6, and (C57BL/6 × BALB/c)Fa [(B × C)F1] strains were purchased 
from  The Jackson  Laboratory,  Bar  Harbor,  Maine.  The  BALB/c  AnN,  C3H/HeN,  and 
B 10.D2/SnN strains were obtained from the Division of Research Services,  National Institutes 
of Health. The B10.M/Sg strain was bred in our animal colony from breeding pairs kindly sent 
by Dr. Jack Stimpfling, Great Falls,  Mont. 
Tumor Cells.  The six BALB/e B lymphoma cell  lines  (A20.3,  M12.4, K46R.18, X16C8.4, 
L10A6.2, and BALENLM 17.7.2) have been previously characterized (18), as has the T  cell 
lymphoma  line  (BALENTL  3)  (19),  and  were  grown  in  a  culture  medium  consisting  of 
Dulbeceo's modified Eagle's medium (DMEM)  (Gibco Laboratories, Grand Island Biological 
Co., Grand Island, N. Y.)  supplemented with 8% fetal calf serum,  15 mM Hepes,  100 U/ml 
penicillin,  100 pg/ml streptomycin, and L-glutamine (300/zg/ml). The phenotypic character- 
istics of each of these cell lines is summarized in Table III. 
Antigens  and Immunizations.  Purified  protein  derivative  of Mycobacterium tuberculosis (PPD) 
(Connaught  Medical  Research  Laboratory,  Willowdale,  Ontario)  was  used  in  culture  at 
20 pg/ml. Pigeon cytochrome c (Sigma Chemical Co., St.  Louis, Mo.) was used in culture at 
100/zg/ml. The random terpolymer poly(Glu57Lys~Phe  s)  (GI_4b  ~) was purchased from Miles- 
Yeda (Rehovot, Israel)  and was used at  50 pg/mouse for immunization and at  50/~g/ml  in 
culture.  Calf skin collagen (Sigma Chemical Co.) was the kind gift  of Dr. Stephen Hedrick, 
(Laboratory of Immunology, National Institute of Allergy and Infectious Diseases)  and was 
used  at  100/~g/mouse  for immunization  and  at  100 #g/ml  in  culture.  Ovalbumin  (OVA) 
purchased from Miles-Yeda was used in culture at  100/zg/ml. All immunizations were carried 
out in the hind footpads by injecting 0.1 ml of an emulsion that contained a 1  : 1 mix of antigen 
in  normal  saline  and  complete  Freund's  adjuvant  (CFA)  that  contained  1 mg/ml  of M. 
tuberculosis strain H37Ra. 
Antisera.  A.TH anti-A.TL  (aIa)  alloantisera  (an  antiserum  made by immunizing A.TH 
mice with A.TL cells) and the monoclonal reagent 14-4-4S (aLE) were the kind gifts of Dr. D. 
H. Sachs and Dr. Keiko Ozato, National Cancer Institute. The monoclonal anti-/-A  k reagent 
(clone 10.2.16), reactive with the public specificity Ia. 17, was kindly provided by Dr. Richard 
Hodes, National Cancer Institute. The anti-LA  d reagent (clone MKD6) was derived by Dr. P. 
Marraek and Dr. J. Kappler (National Jewish Hospital, Denver, Co.) and was the kind gift of 
Dr. J. Berzofsky,  National Cancer Institute. The MKD6 and the 10.2.16 monoclonal reagents 
were  culture  supernatants  and  were  used  at  a  1:15  dilution  in  the  culture  system  for the 
blocking studies shown in Table II. The  14-4-48 was in ascites  form and was used at  1:200 
dilution for the blocking studies.  Monoclonal rat IgG~ anti-ThB antibody (17C9), which reacts 
with  B cells and thymocytes, was purified  from hybridoma culture supernatants  by affinity 
chromatography using a  monoclonal mouse anti-rat  IgGa,2a column and was the kind gift of 
Dr. John Kung (NIAID). 
Antigen-specific T  Cell Proliferation Assay.  T  cells were purified from draining lymph nodes 
(LN) by passage over nylon wool columns, as previously described (7). The nylon-passed cells 
were  then  treated  with  A.TH anti-A.TL alloantiserum  and  complement  to further deplete 
contaminating Ia antigen-positive macrophages. Each 107 cells was treated for 30 min with  1 
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ofa 1:20 dilution of rabbit complement (C; Lo-Tox, Cedarlane Laboratories Limited, Hornby, 
Ontario, Canada). These nylon-passed aIa +  C-treated T  cells were cultured in RPMI  1640 
containing L-glutamine (300  ug/ml),  penicillin (100  U/ml),  streptomycin  (100  #g/ml),  2- 
mercaptoethanol (5 X  10-SM), Hepes buffer (10 mM), and 2.5% human AB serum (obtained 
from a single donor). Cells (2.5 ×  105 cells/0.2 ml) were cultured in flat-bottomed microtiter 
plates together with 1 ×  105 to 2 ×  105 spleen cells or varying numbers of tumor cells, with or 
without antigen. In some instances, APC were pulsed with antigen before addition to cultures. 
These antigen-pulsed presenting cells were prepared  by incubating tumor or spleen cells  in 
PPD 100 #g/ml for 1 h at 37 ° and washing five times in media. 
Spleen cells used as APC received 2,000 rad, and tumor cells received 10,000 tad, using a 137 
Cs irradiator. In all experiments the A20.3 tumor cells were also cultured alone. In addition, in 
some experiments IL-1  and antigen were added to cultures containing tumor cells alone; the 
cpm obtained did not vary whether IL-1  or antigen was  present or absent. Examination of 
stimulated  cultures  containing T  cells  and  A20.3  at  day  4  revealed  that  cells  with  the 
morphology of tumor cells were in a state of degeneration, whereas the blasts present had the 
typical appearance of T  lymphocytes. Stimulation was  assessed  at  day 4  by measuring the 
incorporation of  [3H]thymidine (1  /tCi/well)  (New  England Nuclear,  Boston,  Mass.)  into 
macromolecules. Data  are  expressed  as  the  arithmetic mean cpm.  SE  of the  mean of the 
replicates was  usually <10% of the mean counts and has been omitted from  the tables for 
simplicity. 
Allogeneic Mixed Lymphocyte Response (MLR).  Spleen or lymph node cells  from unprimed 
mice were passed over nylon wool columns and treated with aIa + C. These cells (3 ×  105) were 
cocultured with irradiated spleen cells or tumor cells, as stimulator cells, in round-bottomed 
microtiter wells in 0.2 ml of media, as described above. The response was assayed on day 4 by 
uptake of [3H]thymidine. 
Antigen-reactive and Alloreactive T Cell Lines.  The two antigen-reactive T cell lines (a BALB/c 
OVA-specific line and a  B10.A  pigeon cytochrome c-specific line) were the kind gifts of Dr. 
Maureen Howard and Dr. Louis Matis, respectively (Laboratory of Immunology, NIAID) and 
were prepared by the technique of Kimoto and Fathman (20). The T cells were maintained as 
long-term continuous cultures by alternating 4-d periods of restimulation with antigen and 
syngeneic irradiated (3,300 rad) spleen cells with 10- to 14-d periods without antigen. Antigen- 
reactive T  cells recovered at the end of a  14-d rest  period were used to assay specific  antigen 
presentation by spleen or tumor antigen-presenting  cells. Two alloreactive lines, D3 and M15, 
were prepared from original soft agar colonies by the technique of Sredni et al. (21) and were 
the kind gift  of Dr.  Ronald Schwartz and Mrs.  Chuan Chen  (Laboratory of Immunology, 
NIAID). They are of B10.A origin and are specific for DNP-OVA presented by B10.A APC. In 
addition, line D3 has allospecificity for the H-2  d haplotype, and line M 15 has allospecificity for 
the H-2  f haplotype. The lines were assayed in the following way. T  cells (1  ×  104 to 2 ×  104) 
were cocultured with 1 ×  105 to 5 ×  105 irradiated spleen cells or varying numbers of irradiated 
tumor cells  in the  presence or  absence of antigen in flat-bottomed microtiter wells  in the 
complete media described above, with the exception that 10% fetal calf serum was substituted 
for human serum. [3H]thymidine uptake was assayed on days 3-4. Lines D3 and M15 required 
the presence of an IL-2-containing  EL4 culture supernatant during the culture period. 
IL-I Preparations.  A P388D~ culture supernatant containing IL-1  was the kind gift  of Dr. 
Maureen Howard and Mrs.  Barbara Johnson (Laboratory of Immunology, NIAID) and was 
produced according to the method of Mizel and Mizel (22). Briefly, the P388D1  macrophage- 
like cell  line was  incubated with  1 /xg/ml  of phorbol  myristate acetate  (PMA)  in  media 
containing 1% fetal calf serum. At 5 d the supernatant was harvested and incubated twice with 
inactivated charcoal  to  remove PMA.  Labeling such  supernatants with  radiolabeled PMA 
(New England Nuclear) indicated that charcoal absorption results in removal of>90% of PMA 
(A. L. DeFranco, unpublished observations). The absorbed supernatant was then concentrated 
sevenfold by vacuum dialysis. This preparation contained IL-1 activity, as assayed by induction 
of proliferation of C3H/HeJ  thymocytes in  the  presence of concanavalin A.  A  maximum 
induction of proliferation was seen at a dilution of supernatant of 1:16. In most experiments, 
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culture system.  A highly purified preparation of murine IL-1 was the kind gift of Dr. Steven 
Mizel, Pennsylvania  State University, State College, Pa., and has been recently described (23). 
Results 
A20.3,  an  Ia  Antigen-positive  B  Cell  Tumor,  Can  Stimulate  an  Allogeneic  MLR  in  the 
Presence oflL-1.  Spleen cells that have been enriched for B lymphocytes and depleted 
of splenic adherent cells (SAC) by various maneuvers have been found to be ineffective 
in eliciting allogeneic T  cell proliferation (13).  Because both SAC and B  cells have 
surface Ia molecules, one possibility was that the failure of the B  cell population to 
stimulate was  due  to  the  lack  of some  secretory  product  possessed  by  authentic 
stimulator cells and necessary for eliciting alloreactive T  cell proliferation. A  very 
likely candidate seemed  to  be  II-1  (24).  Indeed, Table I  demonstrates  that  in the 
presence of a small amount of an I1-1-rich P388DI supernatant, an excellent allogeneic 
MLR was obtained using 104 to  105 cells from A20.3, an Ia antigen-positive BALB/c 
B cell tumor line, as stimulator cells. No significant allogeneic MLR was seen in the 
absence of added supernatant. Moreover, the A20.3 tumor cells did not elicit syngeneic 
proliferation, ruling out a  nonspecific stimulatory effect of tumor or viral antigens or 
other immunostimulatory  secretory products. 
TABLE  I 
An la-positive B Cell Tumor Can Stimulate an Allogeneic MLR in the Presence  of lL-1 
[aH]Thymidine uptake of responder cell population* 
Unfractionated  Unfractionated 
Experi-  Stimulator cell  B6 spleen  BALB/c spleen 
ment 
Without  With  Without  With 
IL-1  IL- 1:~  IL-I  IL-I 
None 
BALB/c spleen 
(4x lo~ 
A20.3 (I0~§ 
A20.3 (104) 
None 
BALB/c spleen 
(4×  IO  ~) 
A20.3 (10b)§ 
A20.3 (100 
Acpm 
26,092  15,931  17,236  13,372 
70,916  151,667  11,112  10,451 
22,895  262,540  2,235  5,559 
33,135  59,028  16,840  14,280 
Nylon-passed ala + C-treated B6 spleen 
Without IL-I  With IL-1 
162  1,227 
37,068  109,993 
1,631  234,106 
0  64,684 
* 3 ×  105 responder cells were eocultured with the indicated stimulator cells for 3 d at 37°C 
in round-bottomed microtiter wells. Cultures were pulsed with l#Ci of [aH]thymidine 16 
h before harvesting. 
§ A20.3 tumor cells were irradiated with 10,000 rad using a 137 Cs irradiator. The prolifer- 
ation of irradiated A20.3 cells by themselves  was 28,182 cpm (105) and 8097 cpm (104) in 
experiment 1 and 11,548 cpm (10  B) and 1,942 cpm (104) in experiment 2. These numbers 
have been subtracted from the cpm shown. 
:~ IL-l-containing supernatant from PMA-stimulated P388DI cells was included at a final 
concentration of 1.25%. L.  H. GLIMCHER, K.-J. KIM, I. GREEN, AND W.  E.  PAUL  449 
The responder cell population in experiment  1 was unfractionated spleen cells. To 
rule out the possibility that Ia alloantigens were shed from A20 tumor cells and then 
taken up, reprocessed,  and re-presented  to the T  cells by syngeneic macrophages  in 
the responder cell population, two approaches were taken. First, as shown in Table I, 
experiment 2, the responder cell population was passed over nylon wool columns and 
then  treated  with  an  a-Ia  antiserum  and  C  to  further  deplete  Ia  antigen-bearing 
macrophages. The allogeneic MLR obtained using this population as responder cells 
was  as  good  as  that  obtained  using  unfractionated  spleen  cells  as  the  responder 
population.  Second,  blocking  studies  using  monoelonal  antibodies  directed  at  Ia 
antigens present on either the responder or stimulator cell population were performed 
and demonstrated that antibodies directed at Ia antigens present on A20.3 stimulator 
cells inhibited the aUogeneie MLR. Table II shows that the allogeneic MLR produced 
by coculturing A20.3  stimulator cells  with  C3H(H-2 k)  responder  cells  was  blocked 
62-69% by the inclusion of the anti-I-A  d reagent  (MKD6)  in the culture system, 52- 
69%  by the inclusion of the anti-I-E antibody (14-4-4S)  in the culture supernatant, 
and  86%  when  both  reagents  were  included  in  the  culture  system.  The  anti-I-A  k 
reagent (10.2.16), which is directed at the I region determinants of the responder cell 
population, and the ThB reagent, which is directed against a determinant present on 
B cells and thymocytes, caused no significant inhibition when they were included in 
the culture system.  The allogeneic  MLR  produced by control BALB/c  spleen  cells 
was affected similarly by the above reagents. These same reagents did not significantly 
inhibit, or even enhanced, an allogeneic MLR elicited by B6(H-2 b) stimulator cells. 
Not  All  BALB/c  B  Cell  Tumors  Can  Stimulate  an  Allogeneic  MLR.  A  number  of 
BALB/c B cell tumors have been screened for the expression of and density of surface 
Ia  antigens  (K.  J.  Kim,  manuscript  in  preparation).  These  tumor  cell  lines  were 
TABLE II 
Effect of Monoclonal Anti-Ia Antibodies on the Allogeneic MLR Stimulated by A20.3 cells* 
Stimulator  Antibody 
cell  specificity 
Experiment  1  Experiment  2  Experiment  3 
[3H]Thymidine  Percent  [3H]Thymidine  Percent  Antibody  [aH]Thymidine  Percent 
uptake  inhibition  uptake  inhibition  specificity  uptake  inhibition 
A20.3:~  None  175,391  3=  16,719  --  13,571  4- 2,144 
I-A  a  66,843 3= 7,21 l  62  4,150 3= 300  69 
I-E  54,378 4- 7,151  69  6,577 4- 505  52 
I-A  k  134,315 4- 10,435  24  16,434.4-  3,085  --2 I 
I-A  n +  I-E  ND~  1,909 4- 748  86 
BALB/c  None  189,299 4- 233  147,625 4- 15,357 
I-A  D  58,133 3=  166  69  66,475 4- 2,000  55 
[-E  116,138 4- 9,324  39  66,714 3= 6,695  55 
I.A  j'  170,466 4- 600  10  106,002 "+  13,519  28 
I-A  a +  I-E  ND  27,808 4- 4,136  81 
B6 spleen  None  215,033 3= 10,336  156,505 4- 9,464 
[-A  d  212,894 4- 22,738  1  155,121  3= 15,346  1 
I-E  217,655 3= 6,990  -  1  159,317 3= 26,617  -- 1 
I-A  W  285,516±  16,413  -33  165,3533=  17,743  -11 
I-A  n +  I-E  ND  168,191  3=  16,736  -tl 
None  38,168 4- 3.752  -- 
ThB  30,835 3= 2,478  19 
I-A  a +  I-E  11,842 3= 758  69 
None  93,969 3= 5,544 
ThB  69,794 3= 2,707  26 
I-A  a +  I-E  4,934 4- 1,643  95 
* In  the  first  two experiments,  the  responder  ceils  were  nylon-column  passed,  oda +  C-treated C3H spleen  ceils,  and  in  the  third  experiment,  the 
responder cells were of C57BL/6 origin. The monoclonal reagents, MKD6, directed against a determinant in the I-A  a subregion, and 10.2.16,  directed 
against  a  determinant  in the I-A subregion  of the k haplotype, were included  at a  dilution  of l:15 (vol/vol) in the culture system.  The monoclonal 
reagent  14-4-4S, directed against a determinant  in the I-E subregion  (specificity la7), was in ascite~ form and was included at a dilution of 1:200 in the 
culture system.  The monoclonal  reagent ThB  was affinity-purified  hybrldoma supernatant  and was  used  at  I #g/ml final concentration.  All  three 
experiments  were performed in the presence of 1.25%  IL-I. 
:~ In experiments  I and 3 there were 10  n A20.3 cells per well, and in experiment  2 there were  104 A20.3 cells per well. 
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therefore assayed for their ability to stimulate an allogeneic MLR. The phenotypes of 
these tumors is shown in Table III. Surprisingly, as shown in Table III, only three 
(A20.3, M12.4, and X16C8,4)  of the six tumors were able to stimulate allogeneic T 
cell proliferation; the three remaining tumors (K46R.18, L10A6.2, and BALENLM 
17.7.2)  were ineffective stimulators despite the possession of large amounts of surface 
Ia. There was no obvious correlation between the amount of surface Ia expressed on 
a  tumor  line as  determined  by  fluorescence  activated  cell  sorter  analysis and  its 
stimulatory ability (data  not shown).  Thus,  the  M12  and X16C  tumor cells  have 
relatively little surface Ia but were powerful stimulants, whereas the K46, L10A, and 
BALENLM  17 have large amounts of surface Ia and were poor stimulators. 
A20,3  Stimulates  Proliferation  by  an  H-2 a  but  Not  by  an  H-2 t  Alloantigen-specific 
Line.  Further proof that A20.3 tumor ceils are themselves providing the alloantigenic 
stimulus for T  cell proliferation and not simply providing a  nonspecific stimulus or 
causing the differentiation or activation of APC in residual spleen cells was obtained 
by using two long-term alloreactive B10.A T  cell lines. One of these lines, D3, was 
specific for an alloantigen of the H-2  d haplotype and the other, M15, was directed at 
an alloantigen of the H-2  f haplotype. The results in Table IV show that as few as 5 
×  103 A20.3 cells induced proliferation by the D3 line of a  magnitude greater than 
that  elicited by  105 control BALB/c spleen cells. By contrast,  the A20.3 cells were 
ineffective in stimulating the  M15  line; this  line could, however, be stimulated by 
B 10.M  (H-2  f) spleen cells. Unlike the results obtained using whole populations of T 
cells, proliferation of the cloned T  cells could be elicited in the absence of exogenous 
IL- 1. The reason for this discrepancy is unclear; however, these assays were performed 
in the presence of a  preparation of IL-2. 
A20.3 Presents Antigen to In  Vivo Primed T  Cells.  An Ia antigen-bearing  APC appears 
to be the cell responsible for stimulating both an allogeneic MLR and for presenting 
TABLE III 
Not All BALB/c B Cell Tumors Can Stimulate an Allogeneic MLR* 
Designation 
Stimulator cell surface markers:~  [3H]Thymidine  uptake of 
responder cell 
Syngeneic 
Allogeneic  (B 10.D2) T  Ig  IgM  IgG  Ia§  (B6) T cells 
cells 
Acpm 
None  798  1,025 
B  t0.D2 spleen  47,578  11,408 
A20.3  +  -  "4-  +++  41,258  8,049 
M 12.4  +  -  -  +  44,560  3,050 
X16C 8.4  +  +  -  +  66,280  9,338 
K46R. 18  +  +  -  ++  3,056  338 
BALENLM 17.7.2  +  +  -  ++  3,215  797 
L 10A6.2  +  +  +  +÷  803  646 
* 3 ×  105 nylon-passed  ala + C-treated B6 or B10.D2 spleen responder cells were cocultured for 3 d with 
different B cell tumors (104 cells/well) or with control spleen cells in the presence of 1.25% IL-I. 
:1: All of these tumors were negative for C3R and positive for FcR. 
§ The presence of Ia antigens on these tumor cell lines has been established by immunofluorescence  and 
cytotoxicity with aIa alloantisera (see rcf, 18) and more recently has been confirmed with monoclonal 
anti-Ia reagents on a fluorescence-activated  ceII sorter (Kim et aI., manuscript in preparation). L.  H. GLIMGHER, K.-J.  KIM, I. GREEN,  AND W.  E.  PAUL 
TABLE  IV 
A20.3 Stimulates Only an H-2 a and Not an H-2t Alloantigen-specific Line* 
451 
II-I  Stimulator cells 
[aH]Thymidine uptake 
Line D3 
Experiment  Experiment 
1  2 
Line M15 
None 
1.25% 
Acpm 
None  594  1,833  190 
BALB/c spleen (105)  2,274  11,919  -- 
B10.M (H-2  f) spleen (105)  --$  --  2,380 
A20.3 (104)  12,279  28,030  0 
A20.3 (5 ×  10  a)  18,639  --  469 
A20.3 (10  a)  975  --  162 
None  325  289 
BALB/c spleen (10  ~)  1,976  -- 
B10.M (H-2  t) spleen (10  r')  --  4,669 
A20.3 (104)  24,973  0 
A20.3 (5 ×  10  a)  14,995  611 
A20.3 (10  a)  1,789  248 
* Lines D3 and MI5 are of B10.A origin and are both specific for DNP-OVA. Both lines also 
have an alloreactive specificity. D3 has anti-H-2  J alloreactivity, and M15 has anti-H-2  f 
alloreactivity. In these experiments, 2 X 104 D3 cells and 1 X 104 M 15 cells were cocultured 
with varying numbers (indicated in parentheses) of irradiated A20.3 cells or control spleen 
cells in the presence of 2% IL-2. The addition of IL-2 was necessary because these lines are 
IL-2-dependent. Proliferation was assayed on day 3. 
$ Not done. 
antigen to antigen-reactive T  cells. Table V  demonstrates that a  small number  (10  a 
to  104) of A20.3 cells are capable of presenting three different antigens--OVA, PPD, 
and  G~to  T  cells  from  primed  donors.  Indeed,  10 a  A20.3  cells  stimulated  a 
response that was slightly greater than that stimulated by 105 B10.D2 spleen cells. As 
in  the experiments with  alloreactive T  cells, the antigen-reactive T  cell population 
has been rigorously depleted of Ia-positive cells by nylon column passage followed by 
treatment with an anti-Ia antiserum +  C. The antigen-specific response of this T  cell 
population to antigen in the absence of added antigen-presenting cells was minimal 
as shown,  whereas nylon column  passage alone without  such  treatment  results in a 
very substantial antigen-specific response (not shown). 
The experiments presented in Table V  were performed in the presence of 1.25% of 
the  IL-l-rich  P388D1  PMA-stimulated  supernatant.  However,  unlike  the  results 
obtained in the allogeneic MLR  (Tables I, II, and III), it was not  necessary to add 
exogenous IL-1  to the culture system to obtain a  good antigen-specific response. As 
shown in Table VI, 5  x  10  a A20.3 cells stimulated a  good T  cell response to antigen 
in the absence of added IL-1. This response was, however, clearly magnified by the 
addition  of small  amounts  of either  crude  IL-1  or  of  highly  purified  IL-1.  The 
mechanism  of the  enhancement  of the  proliferation by exogenous  IL-1  is unclear; 
incubation of A20.3 cells with this preparation does not increase the density of surface 
Ia (K. J. Kim, manuscript in preparation). 
Antigen  Pulsing  of A20.3  Cells.  Previous studies  have  demonstrated  that  antigen- 
specific T  cell proliferation can  be  obtained  if the  antigen  is present  continuously 452  ANTIGEN  PRESENTATION  BY  B  CELL  TUMORS 
TABLE  V 
A20.3, M12.4, and X16C8.4 Present Antigen to T Cells from Primed Donors 
[3H]Thymidine uptake* 
Experiment  1  Experiment 2  Experiment 3  Experiment 4  Experiment 5 
OVA response  PPD response  GLd~  response  PPD response  PPD response 
Acpm 
T  alone  2,578  194  495  241 
T  +  B10.D2 spleen:]: 
2 ×  105  41,988  50,297  18,465  11,429 
1 ×  105  28,077  --§  --  5,934 
104  8,726  --  -- 
10  a  4,922  --  -- 
T  +  A20.3 
t0  s  130,965  126,042  44,368  54,725 
104  73,469  142,293  60,825 
10  s  28,821  28,385  -- 
T  +  X16C8.4  --  --  --  13,855 
10  s 
T  +  M12.4  .... 
l0  s 
1,308 
47,241 
39,707 
39,727 
* 2.5 ×  105 nylon column-passed Ma +  C-treated cells from BI0.D2 mice primed with OVA or saline in 
CFA or from (B X C)F1 mice primed with GL~ in CFA in the footpads 8 d earlier were cocultured with 
irradiated spleen cells or varying numbers of A20.3 cells in the presence of IL-I  (1.25%)  with or without 
antigen  (PPD  20 #g/ml, GI.~  50/Lg/ml, and OVA  100 p,g/ml).  Proliferation  was assessed on day 4, 
Results are expressed as cpm obtained in the presence of antigen minus cpm obtained without antigen. 
:~ (B ×  C)FI spleen in experiment 3. 
§ Not done. 
TABLE  VI 
Effect of Exogeneous IL-I on Antigen Presentation by A20.3 to T Cells from 
Primed Donors* 
Experiment  1 
PPD-stimulated [aH]thymidine uptake 
Without  IL-1  Purified IL-1 
IL-I  (1.25%)  (5 U/m0 
Acpm 
T  alone  3,35 l  11,398 
T  +  BI0.D2 spleen (2 X  10S)  70,447  99,884 
T  +  A20.3 (105)  57,262  65,596 
T  +  A20,3 (104)  57,161  92,521 
T  +  A20 (5 x  103)  35,302  68,334 
Experiment 2 
T  alone  238  691 
T  +  Bt0.D2 spleen (2 X  l0  s)  259,626  221,158 
T  +  A20.3 (t0S)  20,993  73,667 
T  +  A20.3 (104)  56,454  170,516 
6,750 
111,215 
82,265 
91,458 
89,799 
* Experimental conditions are the same as described in the footnote to Table V, with 
the exception that cultures were done either (a)  in the absence of exogenous IL-1, 
(b)  in the presence of 1.25%  (vol/vol) of an IL- 1-containing supernatant made by 
stimulating P388Dx  cells with  PMA,  or  (c)  in  the presence of a  highly purified 
preparation oflL-1 kindly donated by Dr. Steven Mizel and recently described (23). L.  H.  GLIMCHER,  K.-J.  KIM,  I.  GREEN,  AND  W.  E.  PAUL  453 
during the culture period or if the APC are first pulsed with the antigen, washed to 
remove unbound antigen, and then cocultured with the antigen-reactive T  cells (25). 
To determine whether A20.3 cells could be effectively pulsed with antigen or if they 
required  the continuous  presence of antigen  to stimulate an antigen-specific T  cell 
response, we incubated A20.3 cells and control spleen cells with PPD (100/~g/ml)  for 
1 h. The cells were then washed extensively (five times) to remove unbound antigen 
and  added  to  PPD-reactive T  cells.  Table  VII shows  that  l05  pulsed  A20.3  cells 
induced  a  T  cell  proliferative  response  that  was  50-90%  as  good  as  the  response 
generated when the antigen was present in the culture medium throughout the assay 
period.  Pulsed  control  spleen  cells  were  40-70%  as  effective  as  spleen  cells  plus 
continuous antigen in this experiment. However, when <105 pulsed A20.3 cells were 
used  in  culture,  no response was stimulated.  In contrast,  as few as  10  a tumor cells 
permitted a good response (40,123 cpm) in the presence of continuous antigen. Again, 
the proliferation obtained was magnified by the addition of the IL-1 preparation to 
the culture system. 
A20.3 Presents Antigen  to In  Vivo Primed  T  Cells and to Long-Term  Antigen-reactive T  Cell 
Lines in a MHCorestricted  Fashion.  In physiological situations, antigen-specific prolif- 
erative responses are only obtained when the antigen-reactive T  cells and the APC 
are derived from donors that share common I region alleles (6, 7). The antigen-specific 
T  cell appears to recognize both an antigenic determinant and a syngeneic I region- 
encoded product on the surface of the APC.  To determine whether A20.3  cells also 
presented antigen in such an MHC-restricted fashion, two different approaches were 
taken. First, Ir gene controlled systems were investigated. In such systems, it is known 
that for the APC to be able to present a  given antigen, the donor of the APC must 
possess a responder allele in the I region (26).  A20.3 cells were tested for their ability 
to present antigen to T  cells from (C57BL/6 ×  BALB/c)F1 mice primed with antigens 
to which one parent was a responder and the other parent a nonresponder. C57BL/6 
mice  possess  an  Ir  gene  enabling  them  to  respond  to  collagen  (27,  28)  but  are 
TABLE  VII 
Presentation of Antigen by Pulsed  A20.3 Cells* 
[aH]Thymidine uptake 
Without IL-1  IL-1  (1.25%)  Purified IL-1  (4 U/ml)~: 
Continuous  Continuous  Continuous  Pulsed  Pulsed  Pulsed  antigen  antigen  antigen 
Acpm 
T  alone  494  --  376  --  520  -- 
T  +  B10.D2 spl.  99,651  59,366  108,304  39,450  106,292  78,081 
T  +  A20.3 105  52,927  38,564  78,437  39,774  67,307  59,031 
T  +  A20.3 104  51,995  0  108,053  0  46,307  0 
T  +  A20.3 5 ×  10  a  28,228  0  104,379  0  67,046  0 
T  +  A20.3 10  a  2,488  0  40,123  0  12,519  0 
* 2.5 ×  l0  B nylon-passed ¢da +  C-treated CFA-primed LN cells from a  B10.D2 animal were cocultured 
with  varying numbers of irradiated  A20.3 cells or  2  X  105 spleen cells in the presence of continuous 
antigen (PPD, 20/tg/ml) or with A20.3 and B10.D2 spleen cells that had been pulsed with 100 #g/ml of 
PPD for  1 h  and extensively washed. The cpm obtained in the absence of antigen has been subtracted 
from the numbers shown above. 
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nonresponders to GI~; BALB/c mice have the reverse response pattern; they respond 
to GI~ but not to collagen. Both parental strains respond to PPD. In this experiment 
(Table VIII), F1 spleen cells were capable of presenting each of the three antigens to 
T  cells  from  primed  F1  donors.  A20.3  cells  which  are  of H-2  d  haplotype,  only 
stimulated  F1 T  cell responses to GI_~ and PPD. They did not stimulate responses to 
collagen to which mice of the H-2  d haplotype are nonresponders. This experiment 
indicates that antigen presentation by A20.3  is regulated by Ir gene products and 
thus strongly argues against the possibility that the A20.3 serves only to induce the 
TABLE  VIII 
A20.3 Presents Antigen in a Genetically Restricted Fashion to T  Cells from a 
Primed Donor 
[aH]Thymidine uptake* 
GI~  Collagen  PPD 
Acpm 
T  alone  41  677  289 
T  +  (B ×  C)F1 spleen  10,884  16,605  53,287 
T  +  A20.3 (105)  18,127  0  89,439 
T  +  A20.3 (104)  14,884  788  113,616 
T  +  A20.3 (5 ×  10  s)  12,600  0  75,234 
* 2.5 ×  105 nylon-passed aIa +  C-treated LN T  cells from a  (B ×  C)F1 animal 
primed  10 d  previously with  100 #g GI~  and  100 p,g of collagen in CFA 
were cocuitured for 4 d with either 2 ×  105 (B ×  C)Fa spleen cells or varying 
numbers of A20.3 cells in the presence of 1.25%  IL-l. Results are expressed 
as the cpm obtained in the presence of antigen minus the cpm obtained with 
media alone. 
TABLE IX 
A20.3 Presents Antigen  in a Genetically Restricted Fashion to Long-Term  T Cell Lines* 
Stimulator cell 
[aH]Thymidine uptake 
Without IL- 1  IL- 1 1.25% 
BALB/c OVA  B10.A pigeon  BALB/c OVA-  B10.A pigeon 
cytochrome c-  specific line  cytochrome c- 
specific line  specific line  specific line 
~m 
None  46  152  179  62 
B 10.D2 spleen  55,457  114  87,748  93 
B 10.A spleen  ND~:  57,934  ND  70,643 
A20.3 104  56,489  3,119  69,167  305 
A20.3 5 ×  l0  s  60,122  ND  89,298  ND 
A20.3 10  a  30,416  0  71,826  557 
* 2 ×  104 T  cells from a BALB/c OVA-specific T  helper line or 1 ×  104 T  cells from a B10.A 
pigeon cytochrome c-specific T  cell proliferative line, prepared according to the method of 
Kimoto and Fathman (20), were cocultured at the end of a  2-wk rest period with 5 ×  10  ~ 
irradiated spleen cells or with varying numbers of A20.3 tumor cells for 3 d in the presence 
or  absence of antigen.  The cultures were  pulsed 8  h  before  harvesting with  1 #Ci  of 
[aH]thymidine. For simplicity, results are expressed as the cpm obtained in the presence of 
antigen minus the cpm obtained with media alone. 
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TABLE X 
Three B Cell Tumors Present Antigen Poorly to Primed T Cells but Do Not 
Suppress the Response Elicited by A20.3 Cells 
Stimulator cell 
PPD-stimulated  [aH]thymidine uptake* 
Stimulator cell 
cpm  cpm 
None  297  K46 + A20.3  124,600 
A20.3  i07,963  LI0.A + A20.3  86,053 
K46R.18  1,640  BALENLM17 + A20.3  117,242 
L10.A6.2  14,106  BALENTL3 + A20.3  115,629 
BALENLM 17.7.2  2,969 
BALENTL3:~  126 
* 2.5 ×  105 nylon-passed otla + C-treated LN cells from B10.D2 mice primed 
with CFA were cocultured for 4 d with  104 irradiated cells from each of the 
tumor lines or with a mixture of 104 A20.3 cells plus 104 cells from each line 
in  the presence of 1.25% IL-1 with  or without  antigen  (PPD  20 #g/ml). 
Results are expressed as the cpm obtained in the presence of antigen minus 
the cpm obtained with media alone. 
A T cell lymphoma with the phenotype Thy-l.2  + Ly-l-2  +, TL  +. Two other 
T cell lymphomas were also tested and were also negative (not shown). 
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differentiation of residual Ia-positive macrophages  in  the T  cell population because 
these  macrophages  would  be  F1  in  haplotype  and  should  therefore  be  capable  of 
stimulating a  proliferative response to collagen as well as to GI-4b and PPD. 
The  second  approach  made  use  of antigen-reactive T  cell  lines.  A  BALB/c  line 
reactive to OVA  and a  B10.A line reactive to pigeon cytochrome c were stimulated 
with varying numbers of A20.3 cells or control spleen cells in the presence of antigen. 
The  data  in  Table  IX  demonstrate  that  as  few as  103  A20.3  cells could  effectively 
present  OVA  to  the  BALB/c  line.  However,  even  104  A20.3  cells failed to  present 
pigeon  cytochrome  c  to  the  I  region-disparate  B10.A  T  cell  line,  Again,  a  good 
response was  obtained  in  the  absence  of exogenous  IL-1, although  the  addition of 
small amounts of IL-1 to this assay clearly magnified the response obtained. 
K46R. 18,  L10A6.2,  and BALENLM  17.7.2  Present Antigen  Poorly  but Do Not Suppress 
Responses  Stimulated  by  A20.3.  In  Table  III we  showed  that  the  M12.4  and  X16C 
lines,  like A20.3,  stimulate  an  allogeneic MLR,  These  two  tumors  are also able to 
present PPD  to primed T  cells (Table V). Three Ia antigen-positive B  cell tumors-- 
K46R. 18,  L10A6.2,  and  BALENLM17.7.2--failed to stimulate an  allogeneic MLR. 
The ability of these tumors to present PPD was tested in a  series of experiments. The 
K46R. 18 tumor failed to present PPD to primed T  cells in four of four experiments; 
the BALENLM 17.7.2 did produce T  cell proliferation when used at the highest dose 
of  105  cells in  one  of three experiments,  and  the  LIOA6.2  produced  modest  T  cell 
proliferation  to  antigen  when  used  at  the  highest  dose  of  l0  s  cells  (Table  X).  A 
possible explanation for the relatively poor ability of K46R.18,  L10A6.2, and BAL- 
ENLM17.7.2  to  present  antigen  was  that  these  particular  B  cell  tumors  secreted 
suppressive  material  into  the culture  supernatant  and  thus  masked  or prevented  a 
proliferative T  cell response. This explanation does not appear to be correct because 
mixing cells  from  each  of these  three  lines  with  A20.3  cells did  not  decrease  the 
excellent proliferative response induced by the latter. 456  ANTIGEN PRESENTATION BY B CELL TUMORS 
Discussion 
The ability to present  protein  antigen or alloantigen  to T  cells in  vitro has been 
shown to reside in an Ia antigen-positive, radioresistant,  adherent,  phagocytic, Ig-, 
FoR  ÷ cell of the macrophage lineage (8). More recently, Steinman and his co-workers 
(12)  have provided  convincing  evidence  that  the  lymphoid  dendritic  cell  which  is 
present in very small numbers in mouse spleen and that differs from the macrophage 
in being nonphagocytic and FcR-, is an extremely potent stimulator of alloreactive 
T  cells, and Sunshine  et al.  (29)  have further shown its effectiveness as an antigen- 
presenting cell. In addition, Chesnut and Grey (15) have reported that normal B cells 
can, under certain circumstances, present antigen to antigen-reactive T  cells. In this 
paper we  present  data  that  demonstrate  that  several  but  not  all  of a  series  of Ia 
antigen-positive  BALB/e  B  cell  lymphomas  grown  in  tissue  culture  can  present 
alloantigens and protein antigens to alloreactive and antigen-reactive T  cells. One of 
these  tumors  A20.3,  was  chosen  for  further  study.  Antigen  presentation  and  allo- 
stimulation  by this  B  cell tumor line  appeared to  have the same characteristics  as 
those  attributed  to  the  conventional  APC  because  (a)  the  tumor  cells  presented 
antigen  in  an  MHC-restricted  fashion  to  antigen-reactive  T  cells,  (b)  alloantigen 
presentation  was blocked by the  inclusion  of monoclonal  anti-Ia antibodies  in  the 
culture system, (c) tumor cells could be effectively pulsed with soluble antigen, and 
(d) on a per cell basis A20.3 appeared to be at least as powerful as conventional APC 
in whole spleen because  108 A20.3 cells were as effective in inducing proliferation as 
l0  s irradiated spleen cells (Table V). 
The statement that tumor cells with the characteristics of B cells can serve as APC 
and  stimulators  of  alloreactive  responses  depends  upon  the  demonstration  that 
contaminating macrophages remaining in the T  cell population were not the source 
of  the  antigen-presenting  function.  Residual  Ia  antigen-positive  APC  could  also 
potentially  explain  the  alloantigenic  stimulation  we obtained because such  macro- 
phages in the responder cell population could take up, process, and re-present shed Ia 
antigens  from the  allogeneic tumor cells.  That  such  a  phenomenon  does occur for 
cytotoxic cells has been shown by Weinberger et al. for purified H-2 complex proteins 
(24). 
To address this issue, three approaches were taken. First, we routinely treated the 
antigen-reactive and alloreactive nylon-passed T  cell population with an ~xIa +  C  to 
deplete  residual  contaminating  APC.  The  data  obtained  indicate  that  A20.3  ceils 
induced  an excellent  allogeneic and  antigen-specific response in  such  pretreated T 
cell populations. The effectiveness of the aIa treatment was demonstrated by the lack 
of an antigen-specific response from the treated T  cell population in the absence of 
added tumor or spleen cells as APC, even in the presence of a source of exogenous IL- 
l.  Second,  we  demonstrated  that  the  inclusion  of monoclonal  antibodies  directed 
against stimulator cell Ia molecules (MKD6 and  14.4.4S)  could inhibit the prolifera- 
tion  observed;  a  monoelonal antibody directed  against  responder cell  Ia molecules 
(10.2.16) was not inhibitory. Finally, the activation of allospecific and antigen-specific 
T  cell  lines  by the  A20.3  provides  strong  evidence  that  the  tumor  cell  was  itself 
providing the alloantigenic  or protein  antigen  stimulus  for T  cell proliferation  and 
not  simply causing  the  differentiation  or  activation  of residual  Ia antigen-positive 
APC  in  the T  cell population.  Indeed,  the capacity of A20.3  of H-2  a haplotype to L.  H.  GLIMCHER,  K.-J.  KIM,  I.  GREEN,  AND  W.  E.  PAUL  457 
activate primed F1 T cells accorded with the Ir phenotype of H-2  d cells. That is, A20.3 
was capable of presenting GI_4b but not collagen to F1 T  cells. 
One interesting difference between the antigen-specific and allospecific responses 
studied in this paper was the necessity for the addition of an exogeneous source of IL- 
l  to obtain an allogeneic MLR. Although the addition of IL- 1 clearly enhanced the 
proliferation  generated  by  antigen-specific  T  cells,  it  was  not  necessary.  A  good 
proliferative response could be obtained in its absence. Studies by Weinberger et al. 
(24) suggested that a  factor, presumably elaborated by the accessory cells, as well as 
macrophage-bound antigen, was necessary for stimulation of an alloreactive response. 
We  have  not  been  able  to  demonstrate  constitutive  IL-1  production  by  the  B 
lymphoma cell lines, but it is possible that  they do produce small amounts of IL-1 
during the culture period. Alternatively, there may be another source of IL-1 in these 
cultures. These amounts might be sufficient to provide the second signal for antigen- 
reactive T  cells but insufficient to trigger alloantigen-reactive T  cells. 
We cannot explain the relatively poor ability of three of the six BALB/c B  cell 
tumors  to  either stimulate  an  allogeneic MLR  or to  present  antigen.  It  does  not 
appear to be related to surface Ia antigen density (K. J. Kim, unpublished observation) 
nor do these tumors appear to produce suppressive secretory products. The diminished 
capacity of these cells to present antigen even in the presence of exogeneous IL-1 also 
makes a simple lack of secretion of this factor unlikely as an explanation. It is possible 
that there is yet another factor required to trigger antigen-reactive T cells and secreted 
by classic APC and by three of the six B cell tumors discussed here but not secreted 
by  the  three  poorly stimulatory  tumors.  Alternatively,  a  defect  in  taking  up  and 
presenting antigen might be responsible, although the fact that these B cells tumors 
are nonstimulatory in an allogeneic MLR as well as poorly stimulatory in a protein 
antigen-specific response makes this less likely. 
A cloned and easily obtainable population of B lymphoma cells endowed with the 
ability to present alloantigen and protein antigen to alloreactive and antigen-reactive 
T  cells  in  an  MHC-restricted  fashion  as  efficiently  on  a  per  cell  basis  as  the 
conventional APC should provide a useful model system to examine the biochemical 
events involved in antigen uptake, processing, and I region-associated antigen presen- 
tation to long-term continuous antigen-reactive T  cell lines. 
Summary 
Several Ia-positive BALB/c B  cell tumor lines were screened for their ability to 
present alloantigen and protein antigens to alloreactive and antigen-reactive T  cells. 
Of six  Ia-positive tumor lines studied,  three were found to be effective as  antigen 
presenting cells (APC). Indeed, on a per cell basis, one of the stimulatory lines, A20.3, 
was  substantially  more  effective  than  whole  spleen  cells.  The  other  three  lines, 
although Ia-positive, were nonstimulatory. A20.3 was chosen for further study. This 
tumor appeared  to behave like the conventional APC  because  (a)  the  tumor cells 
presented  alloantigen,  (b)  they  presented  protein  antigen  in  an  MHC-restricted 
fashion to both primed donor T  cells and  to long-term continuous T  cell lines,  (c) 
alloantigen presentation was blocked by the inclusion of an anti-Ia antibody in the 
culture system, and (d) A20.3 cells could be effectively pulsed with antigen, although 
the  continuous  presence  of antigen  in  the  culture  system  resulted  in  a  superior 
response. The addition of an exogenous source of interleukin  1 proved necessary to 458  ANTIGEN  PRESENTATION  BY  B CEI,L TUMORS 
obtain  an  alloreactive  but  not  an  antigen-specific  T  cell  response,  although  its 
inclusion did enhance the magnitude of antigen-stimulated proliferation. These tumor 
cells should prove useful in studying the biochemical events that occur during antigen 
processing and the requirements for T  cell triggering by processed antigen in associ- 
ation with Ia molecules. 
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